Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904682 · ClinicalTrials.gov registry record · Phase 2
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
A Phase 2 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01904682 is a Phase 2 study that has completed, run by Traws Pharma. The registered enrollment target is 45 participants.
The verdict
NCT01904682, a Phase 2 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The study will enroll low risk MDS patients who need red blood cell transfusions and who are refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study is to determine whether oral rigosertib treatment results in hematological improvements according to the 2006 International Working Group criteria in these patients. The study will also record any side effects that may occur during the study.
Interventions
- DRUG Oral rigosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-07 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904682
The ClinicalTrials.gov registry entry for NCT01904682 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral rigosertib is the first listed.
NCT01904682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01904682 about?
NCT01904682 is a clinical study titled "Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs". The study will enroll low risk MDS patients who need red blood cell transfusions and who are refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study is to determine whether oral rigosertib treatment results in hematological improvements according to the 2006 Intern...
What is the current status of trial NCT01904682?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2013-07. Estimated completion is 2021-05.
What interventions are being tested in trial NCT01904682?
The interventions under investigation include: Oral rigosertib (DRUG).
Who is sponsoring clinical trial NCT01904682?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.